



Targeted Radionuclide Diagnosis and Therapy of Prostate Cancer— From Basic Research to Clinical Perspectives

Guest Editor:

Prof. Dr. Anna Lankoff

1. Centre for Radiobiology and
Biological Dosimetry, Institute of
Nuclear Chemistry and
Technology, Dorodna 16, 03-195
Warsaw, Poland

2. Department of Medical
Biology, Institute of Biology, Jan
Kochanowski University,
Uniwersytecka 7, 24-406 Kielce,
Poland

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editor

Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related death. Due to the significant mortality and morbidity rate associated with the progression of this disease, there is an urgent need for the development and application of precise diagnostic imaging agents and effective therapeutic strategies for prostate cancer patients. In recent years, tremendous progress has been made in managing prostate cancer patients, partially due to achievements in radioligand-driven imaging and therapy. This Special Issue welcomes original research articles, communications and review articles dealing with the design, synthesis, and evaluation of new potentially active radiopharmaceuticals for the radionuclide-targeted diagnosis and therapy of prostate cancer. Studies using pre- and clinical data on radiotheranostics and nanoparticle-based radiopharmaceutical applications in prostate cancer diagnosis and therapy, including their safety and efficacy, are also welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

Contact Us

Molecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](#)